Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Christopher L. Moertel, MD
Advertisement
Articles by Christopher L. Moertel, MD
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
2
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
3
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
4
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
5
